What is IMUX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IMUX?

P/E (TTM) is n/a and 52-week range is $5.06 to $17.43 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IMUX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IMUX?

The company profile lists net income (TTM) near $-57M, EPS (TTM) near $-4.20 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Immunic Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 13.6M shares outstanding, ISIN US4525EP2001 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Immunic Inc

$IMUX

Health Care · Biotechnology

IR Run Scenarios

$8.19

+8.33%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Immunic Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2014-04-17. Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Employees

Website

imux.com

IPO

2014-04-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)